Mazdutide (IBI362) Dosing Protocol: Dual GLP-1/Glucagon Guide
Also known as: IBI362, LY3305677, Oxyntomodulin Dual GLP-1/Glucagon Agonist
Studied in published research — not a medical recommendation. Primary protocol (GLORY-1 Phase 3 Standard Escalation Protocol (6 mg)): 2.0 mg (Wks 1–4) → 4.0 mg (Wks 5–8) → 6.0 mg maintenance (Wks 9–48), Once weekly.
Once weekly
Research-reported range; the linked study used a different dose or units. Phase 3 GLORY-1 protocol; 4 mg and 6 mg maintenance cohorts achieved 12.1% to 14.8% body weight reduction at 48 weeks
Subcutaneous injection
Human clinical trials or FDA-approved formulation exists
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 2 doses in the vial at the low end.
Save Mazdutide to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a GLP-1 Agonist?
A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.
Bottom Line Up Front
Mazdutide (IBI362 / LY3305677) is a once-weekly mammalian oxyntomodulin analog that co-activates GLP-1 and Glucagon receptors. Phase 3 GLORY-1 (NEJM 2025) demonstrated up to 14.8% weight loss at 6 mg (and up to 18.6% at 9 mg in GLORY-2) alongside 73%–80% liver fat reduction.
Obesity weight reduction (Phase 3 RCT), hepatic steatosis/MASH clearance, and uric acid/triglyceride lowering
Head-to-head superiority over triple agonist Retatrutide at 12 mg
Xinermei (Innovent / Eli Lilly — NMPA Approved 2025; Phase 3 Global)
3 (1 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Mazdutide is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
Mazdutide is a long-acting synthetic peptide analog of mammalian oxyntomodulin originally discovered by Eli Lilly (LY3305677) and co-developed with Innovent Biologics (IBI362). Unlike pure GLP-1 mono-agonists (semaglutide) that rely primarily on caloric restriction via central satiety, Mazdutide balances GLP-1 receptor agonism with hepatic Glucagon receptor (GCGR) activation. This dual signaling simultaneously suppresses appetite while increasing resting energy expenditure, hepatic beta-oxidation, and lipolysis, while clearing liver fat and serum uric acid.
Mechanisms of Action
- Agonizes GLP-1 receptors in the hypothalamus and pancreas to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion
- Activates hepatic Glucagon receptors (GCGR) to stimulate mitochondrial fatty acid oxidation, glycogenolysis modulation, and resting thermogenesis
- Reduces hepatic de novo lipogenesis, achieving 73%–80% relative liver fat reduction in MASLD/MASH sub-studies
- Fatty-acid acylation side chain binds serum albumin, extending elimination half-life to ~10–11 days for smooth once-weekly subcutaneous dosing
Research Protocols
Summaries of published research. For educational purposes only.
Metabolic, Hepatic & Incretin Safety Biomarker Panel (Mazdutide)
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Related Studies
In 610 adults with overweight or obesity randomized to Mazdutide 4 mg, 6 mg, or placebo for 48 weeks, Mazdutide achieved up to 14.8% weight loss along with marked reductions in waist circumference, blood pressure, LDL/triglycerides, ALT/AST, and serum uric acid.
Limitations: Conducted primarily in Chinese adult cohorts; Western global Phase 3 trials ongoing.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Approved by China NMPA in 2025; remains investigational / non-FDA-approved in the United States
- •Glucagon receptor co-agonism can modestly increase resting heart rate (+2 to +5 bpm)
- •Transient gastrointestinal effects (nausea, diarrhea, decreased appetite) occur primarily during 4-week dose escalations
- •Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or MEN2
Where to get Mazdutide, baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Related Peptides
More metabolic peptides
Semaglutide
Semaglutide is a GLP-1 receptor agonist that mimics the horm...
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It rep...
Retatrutide
Retatrutide is a triple hormone receptor agonist developed b...
Liraglutide
Liraglutide is an FDA-approved GLP-1 receptor agonist used f...
AOD-9604 (hGH Frag 176-191)
AOD-9604 is a modified fragment of human growth hormone (hGH...
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.